Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard Furie, Raj Tummala, Theresa Lawrence Ford et al.|The Lancet Rheumatology|2019Cited by 478
A Randomized, <scp>Placebo‐Controlled</scp> Phase <scp>III</scp> Extension Trial of the <scp>Long‐Term</scp> Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth Kalunian, Hussein Al‐Mossawi, Richard Furie et al.|Arthritis & Rheumatology|2022Cited by 151
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Raj Tummala, Gabriel Abreu et al.|Annals of the Rheumatic Diseases|2022Cited by 141